BMO Capital Gives Cronos Group (CRON) Lower Rating; Capricor Therapeutics (CAPR) Sentiment Is 0.67

BMO Capital has cut Cronos Group Inc (CRON) stock rating to Sell in an analyst note revealed to investors on Monday morning.

Capricor Therapeutics Inc (CAPR) investors sentiment decreased to 0.67 in 2018 Q4. It’s down -1.33, from 2 in 2018Q3. The ratio fall, as 4 institutional investors started new and increased holdings, while 6 sold and reduced their stock positions in Capricor Therapeutics Inc. The institutional investors in our database now possess: 1.51 million shares, down from 2.05 million shares in 2018Q3. Also, the number of institutional investors holding Capricor Therapeutics Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 5 Increased: 3 New Position: 1.

More recent Capricor Therapeutics, Inc. (NASDAQ:CAPR) news were published by: which released: “Capricor Therapeutics -2% on DMD trial halt – Seeking Alpha” on December 26, 2018. Also published the news

... read more at: